Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era

• Published in: Medicine (Baltimore) 2017-03, Vol.96 (10), p.e6230-e6230
• Main Authors: Iordache, Laura, Bengoufa, Djaouida, Taulera, Olivier, Rami, Agathe, Lascoux-Combe, Caroline, Day, Nesrine, Parrinello, Maguy, Sellier, Pierre-Olivier, Molina, Jean-Michel, Mahr, Alfred
• Format: Article
• Language: English
• Subjects: Adult; Antiretroviral Therapy, Highly Active; Autoantibodies - blood; Cross-Sectional Studies; Female; HIV Infections - blood; HIV Infections - drug therapy; HIV Infections - immunology; Humans; Male; Middle Aged; Observational Study
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000006230

Nonorgan-specific autoantibodies (AAbs) are used for diagnosing autoimmune diseases but can also be detected in other conditions. We carried out a cross-sectional study with the aim to screen HIV1-infected patients in the era of highly active antiretroviral therapy (HAART) for AAbs and to analyze the association of their presence with hypergammaglobulinemia and immunovirological status.Blood samples from HIV1-infected patients without major concomitant illnesses followed in 2 hospitals in Paris, France were tested for immunovirological status, serum immunoglobulin G (IgG) level, antinuclear antibodies (ANAs), anti-double-stranded DNA (anti-dsDNA), anti-extractable nuclear antigens (anti-ENAs), anticardiolipin (aCL), anti-β2glycoprotein1 (anti-β2GP1), and antineutrophil cytoplasmic antibodies (ANCAs). Clinically relevant AAbs were defined as ANAs with titers ≥1:160, anti-dsDNA or anti-ENA antibodies; aCL or anti-β2GP1 antibodies with a level ≥40 U/ml; and ANCAs reacting with proteinase 3 or myeloperoxidase.We included 92 patients (mean age 47 years, men 55%, sub-Saharan African background 55%, HAART 85%, mean CD4 lymphocyte count 611/mm, viral load